⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21955854 | 1.00 | — | — | |
| SCHEMBL7335094 | 1.00 | — | — | |
| SCHEMBL1534982 | 0.79 | — | — | |
| SCHEMBL2032829 | 0.79 | — | — | |
| SCHEMBL738238 | 0.79 | — | — | |
| SCHEMBL223812 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL1217456 | 0.77 | DPP4 (0.43) | — | |
| SCHEMBL254738 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL14152640 | 0.77 | DPP4 (0.43) | — | |
| SCHEMBL223813 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220202948-A1 | Agent for Eliminating Pluripotent Stem Cells | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-06-30 | — | — | US | disclosed |
| US-20220144889-A1 | Hemiasterlin Derivative Having Cysteine Residue | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-05-12 | — | — | US | disclosed |
| US-20220125941-A1 | Hemiasterlin Derivative and Antibody-Drug Conjugate Thereof | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-04-28 | — | — | US | disclosed |
| US-20200247847-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-06 | — | — | US | disclosed |
| US-20200247845-A1 | Hemiasterlin Derivatives and Antibody-Drug Conjugates Including Same | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-06 | — | — | US | disclosed |
| EP-0648205-B1 | PEPTIDYL DERIVATIVES AS METALLOPROTEINASE INHIBITORS | CELLTECH THERAPEUTICS LTD (GB) | 1999-07-14 | — | — | EP | disclosed |
| US-5714491-A | ANTICANCER AND ANTITUMOR AGENT | CELLTECH THERAPEUTICS LIMITED (GB) | 1998-02-03 | — | — | US | disclosed |
| EP-0648205-A1 | PEPTIDYL DERIVATIVES AS METALLOPROTEINASE INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1995-04-19 | — | — | EP | disclosed |
| WO-1994025434-A1 | PEPTIDYL DERIVATIVES AS METALLOPROTEINASE INHIBITORS | CELLTECH LIMITED (GB) | 1994-11-10 | — | — | WO | disclosed |
| CN-1018824-B | Process for preparing 4, 4-dialkyl-2-azetidinones | SQUIBB & SONS INC (US) | 1992-10-28 | — | — | CN | disclosed |
| CN-1014894-B | Process for preparing 4, 4-dialkyl-2-azetidinones | SQUIBB & SONS INC (US) | 1991-11-27 | — | — | CN | disclosed |
| CN-1055736-A | 4, the preparation method of 4-dialkyl group-2-azetidinones | SQUIBB & SONS INC (US) | 1991-10-30 | — | — | CN | disclosed |
| US-4694083-A | Certain carbamate ester derivatives forming salts with pyridinium or picolinium cations which are useful as intermediates | E. R. SQUIBB & SONS, INC. (US) | 1987-09-15 | — | — | US | disclosed |
| US-4684722-A | ANTIBIOTICS | E. R. SQUIBB & SONS, INC. (US) | 1987-08-04 | — | — | US | disclosed |
| EP-0229012-A1 | Monosulfactams | E.R. Squibb & Sons, Inc. (US) | 1987-07-15 | — | — | EP | disclosed |
| US-4638061-A | [3S(Z)]-2-[[[1-(2-amino-4-thiazolyl)-2-[[2,2-dimethyl-4-oxo-1-(sulfooxy)-3-azetidinyl]amino]-2-oxoethylidene]-amino]oxy] acetic acid and intermediate | E. R. SQUIBB & SONS, INC. (US) | 1987-01-20 | — | — | US | disclosed |
| CN-86100736-A | Process for preparing 4, 4-dialkyl-2-azetidinones | — | 1986-10-22 | — | — | CN | disclosed |